{
  "name": "Top 17 Targets - 2025-12-07",
  "description": "Algorithmically identified M&A targets",
  "created_date": "2025-12-07T09:09:37.737128",
  "last_updated": "2025-12-07T09:09:37.737129",
  "targets": [
    {
      "ticker": "REPL",
      "name": "Replimune Group",
      "therapeutic_area": "oncology_adc",
      "lead_asset": "RP1",
      "development_stage": "Phase 3",
      "market_cap": 1150000000,
      "ma_score": 69.15,
      "rank": 1,
      "deal_probability_12mo": 0.49575,
      "top_acquirer": "Daiichi Sankyo (95% fit, 38% probability)",
      "estimated_deal_value": "$1.50B - $2.07B (base: $1.73B)"
    },
    {
      "ticker": "PRAX",
      "name": "Praxis Precision Medicines",
      "therapeutic_area": "cns_neuropsychiatry",
      "lead_asset": "Ulixacaltamide",
      "development_stage": "Phase 3",
      "market_cap": 1280000000,
      "ma_score": 68.0,
      "rank": 2,
      "deal_probability_12mo": 0.59,
      "top_acquirer": "AbbVie (90% fit, 36% probability)",
      "estimated_deal_value": "$1.66B - $2.30B (base: $1.92B)"
    },
    {
      "ticker": "RLAY",
      "name": "Relay Therapeutics",
      "therapeutic_area": "oncology_adc",
      "lead_asset": "RLY-2608",
      "development_stage": "Phase 2",
      "market_cap": 1850000000,
      "ma_score": 67.30000000000001,
      "rank": 3,
      "deal_probability_12mo": 0.5865,
      "top_acquirer": "Daiichi Sankyo (95% fit, 38% probability)",
      "estimated_deal_value": "$2.40B - $3.33B (base: $2.77B)"
    },
    {
      "ticker": "ANNX",
      "name": "Annexon Biosciences",
      "therapeutic_area": "autoimmune",
      "lead_asset": "ANX005",
      "development_stage": "Phase 3",
      "market_cap": 890000000,
      "ma_score": 67.25,
      "rank": 4,
      "deal_probability_12mo": 0.5862499999999999,
      "top_acquirer": "Johnson & Johnson (90% fit, 36% probability)",
      "estimated_deal_value": "$1.16B - $1.60B (base: $1.33B)"
    },
    {
      "ticker": "AURA",
      "name": "Aura Biosciences",
      "therapeutic_area": "radiopharmaceuticals",
      "lead_asset": "AU-011",
      "development_stage": "Phase 3",
      "market_cap": 725000000,
      "ma_score": 66.8,
      "rank": 5,
      "deal_probability_12mo": 0.484,
      "top_acquirer": "Novartis (90% fit, 36% probability)",
      "estimated_deal_value": "$0.94B - $1.30B (base: $1.09B)"
    },
    {
      "ticker": "IGMS",
      "name": "IGM Biosciences",
      "therapeutic_area": "oncology_adc",
      "lead_asset": "Imvotamab",
      "development_stage": "Phase 2",
      "market_cap": 680000000,
      "ma_score": 66.75,
      "rank": 6,
      "deal_probability_12mo": 0.6337499999999999,
      "top_acquirer": "Daiichi Sankyo (95% fit, 38% probability)",
      "estimated_deal_value": "$0.88B - $1.22B (base: $1.02B)"
    },
    {
      "ticker": "FUSN",
      "name": "Fusion Pharmaceuticals",
      "therapeutic_area": "radiopharmaceuticals",
      "lead_asset": "FPI-1434",
      "development_stage": "Phase 2",
      "market_cap": 850000000,
      "ma_score": 66.3,
      "rank": 7,
      "deal_probability_12mo": 0.48149999999999993,
      "top_acquirer": "Novartis (90% fit, 36% probability)",
      "estimated_deal_value": "$1.10B - $1.53B (base: $1.27B)"
    },
    {
      "ticker": "TBPH",
      "name": "Theratechnologies",
      "therapeutic_area": "rare_disease",
      "lead_asset": "Tesamorelin",
      "development_stage": "Phase 3",
      "market_cap": 580000000,
      "ma_score": 66.0,
      "rank": 8,
      "deal_probability_12mo": 0.63,
      "top_acquirer": "Sanofi (85% fit, 34% probability)",
      "estimated_deal_value": "$0.75B - $1.04B (base: $0.87B)"
    },
    {
      "ticker": "XNCR",
      "name": "Xencor",
      "therapeutic_area": "autoimmune",
      "lead_asset": "Plamotamab",
      "development_stage": "Phase 2",
      "market_cap": 1450000000,
      "ma_score": 64.80000000000001,
      "rank": 9,
      "deal_probability_12mo": 0.37400000000000005,
      "top_acquirer": "Johnson & Johnson (90% fit, 36% probability)",
      "estimated_deal_value": "$1.89B - $2.61B (base: $2.17B)"
    },
    {
      "ticker": "ELEV",
      "name": "Elevation Oncology",
      "therapeutic_area": "oncology_adc",
      "lead_asset": "Seribantumab",
      "development_stage": "Phase 2",
      "market_cap": 620000000,
      "ma_score": 64.75,
      "rank": 10,
      "deal_probability_12mo": 0.47375,
      "top_acquirer": "Daiichi Sankyo (95% fit, 38% probability)",
      "estimated_deal_value": "$0.81B - $1.12B (base: $0.93B)"
    },
    {
      "ticker": "SAGE",
      "name": "Sage Therapeutics",
      "therapeutic_area": "cns_neuropsychiatry",
      "lead_asset": "Zuranolone",
      "development_stage": "Approved",
      "market_cap": 1650000000,
      "ma_score": 64.5,
      "rank": 11,
      "deal_probability_12mo": 0.7225,
      "top_acquirer": "AbbVie (90% fit, 36% probability)",
      "estimated_deal_value": "$2.15B - $2.97B (base: $2.48B)"
    },
    {
      "ticker": "GPCR",
      "name": "Structure Therapeutics",
      "therapeutic_area": "obesity_glp1",
      "lead_asset": "GSBR-1290",
      "development_stage": "Phase 2",
      "market_cap": 3200000000,
      "ma_score": 64.2,
      "rank": 12,
      "deal_probability_12mo": 0.371,
      "top_acquirer": "Novo Nordisk (95% fit, 38% probability)",
      "estimated_deal_value": "$4.16B - $5.76B (base: $4.80B)"
    },
    {
      "ticker": "ALT",
      "name": "Altimmune",
      "therapeutic_area": "obesity_glp1",
      "lead_asset": "Pemvidutide",
      "development_stage": "Phase 2",
      "market_cap": 950000000,
      "ma_score": 64.15,
      "rank": 13,
      "deal_probability_12mo": 0.47075,
      "top_acquirer": "Novo Nordisk (95% fit, 38% probability)",
      "estimated_deal_value": "$1.24B - $1.71B (base: $1.43B)"
    },
    {
      "ticker": "IMCR",
      "name": "Immunocore Holdings",
      "therapeutic_area": "immunology",
      "lead_asset": "Kimmtrak",
      "development_stage": "Approved",
      "market_cap": 2350000000,
      "ma_score": 60.9,
      "rank": 14,
      "deal_probability_12mo": 0.3545,
      "top_acquirer": "Pfizer (70% fit, 28% probability)",
      "estimated_deal_value": "$3.06B - $4.23B (base: $3.52B)"
    },
    {
      "ticker": "RVMD",
      "name": "Revolution Medicines",
      "therapeutic_area": "oncology_adc",
      "lead_asset": "RMC-6236",
      "development_stage": "Phase 2",
      "market_cap": 7200000000,
      "ma_score": 60.5,
      "rank": 15,
      "deal_probability_12mo": 0.3025,
      "top_acquirer": "Daiichi Sankyo (95% fit, 38% probability)",
      "estimated_deal_value": "$9.36B - $12.96B (base: $10.80B)"
    },
    {
      "ticker": "VKTX",
      "name": "Viking Therapeutics",
      "therapeutic_area": "obesity_glp1",
      "lead_asset": "VK2735",
      "development_stage": "Phase 2",
      "market_cap": 6800000000,
      "ma_score": 58.8,
      "rank": 16,
      "deal_probability_12mo": 0.294,
      "top_acquirer": "Novo Nordisk (95% fit, 38% probability)",
      "estimated_deal_value": "$8.84B - $12.24B (base: $10.20B)"
    },
    {
      "ticker": "KRYS",
      "name": "Krystal Biotech",
      "therapeutic_area": "rare_disease",
      "lead_asset": "Vyjuvek",
      "development_stage": "Approved",
      "market_cap": 4800000000,
      "ma_score": 57.55,
      "rank": 17,
      "deal_probability_12mo": 0.28775,
      "top_acquirer": "Sanofi (85% fit, 34% probability)",
      "estimated_deal_value": "$6.24B - $8.64B (base: $7.20B)"
    }
  ],
  "statistics": {
    "total_targets": 17,
    "avg_ma_score": 64.57058823529412,
    "avg_market_cap": 2177941176.470588,
    "avg_deal_probability": 0.4787352941176471,
    "total_estimated_value": 55537500000.0,
    "therapeutic_areas": [
      "rare_disease",
      "immunology",
      "obesity_glp1",
      "radiopharmaceuticals",
      "oncology_adc",
      "autoimmune",
      "cns_neuropsychiatry"
    ],
    "high_probability_targets": 11
  }
}